Sanofi Genzyme
Boost for AZ as Ultomiris gets CHMP nod for expanded label
Phil Taylor
Alexion, AstraZeneca, Kyowa Kirin, Nexviadyme, Nouryant, Parkinson's disease, Pompe disease, rare disease, Sanofi Genzyme, Soliris, Ultomiris
0 Comment
Sanofi’s venglustat bombs again, but isn’t dead yet
Phil Taylor
kidney disease, nephrology, rare disease, Sanofi, Sanofi Genzyme, venglustat
0 Comment
Switch data back Chiesi/Protalix long-acting Fabry drug
Phil Taylor
Chiesi, Fabrazyme, Fabry disease, Protalix, rare disease, Replagal, Sanofi Genzyme, Takeda
0 Comment
Deep Dive/ Patients/ Views & Analysis/ Views and analysis
Finding agility in unprecedented times
mike.hammerton@pharmaphorum.com
COVID-19, Deep Dive, Nicole Farmer, patients, Patients and Partnerships 2020, Sanofi Genzyme
0 Comment
Oncology/ Views & Analysis/ Views and analysis
Sanofi Genzyme UK medical boss Marc Moodley discusses oncology plans, NICE and Brexit
Richard Staines
Brexit, cancer, Genzyme, Marc Moodley, NICE, Sanofi, Sanofi Genzyme
0 Comment